177 related articles for article (PubMed ID: 35715193)
1. Neutrophil lymphocyte ratio as an indicator for disease progression in Idiopathic Pulmonary Fibrosis.
Achaiah A; Rathnapala A; Pereira A; Bothwell H; Dwivedi K; Barker R; Iotchkova V; Benamore R; Hoyles RK; Ho LP
BMJ Open Respir Res; 2022 Jun; 9(1):. PubMed ID: 35715193
[TBL] [Abstract][Full Text] [Related]
2. Neutrophil levels correlate with quantitative extent and progression of fibrosis in IPF: results of a single-centre cohort study.
Achaiah A; Fraser E; Saunders P; Hoyles RK; Benamore R; Ho LP
BMJ Open Respir Res; 2023 Oct; 10(1):. PubMed ID: 37816551
[TBL] [Abstract][Full Text] [Related]
3. Monocyte and neutrophil levels are potentially linked to progression to IPF for patients with indeterminate UIP CT pattern.
Achaiah A; Rathnapala A; Pereira A; Bothwell H; Dwivedi K; Barker R; Benamore R; Hoyles RK; Iotchkova V; Ho LP
BMJ Open Respir Res; 2021 Nov; 8(1):. PubMed ID: 34799353
[TBL] [Abstract][Full Text] [Related]
4. Serial decline in lung volume parameters on computed tomography (CT) predicts outcome in idiopathic pulmonary fibrosis (IPF).
Robbie H; Wells AU; Fang C; Jacob J; Walsh SLF; Nair A; Camoras R; Desai SR; Devaraj A
Eur Radiol; 2022 Apr; 32(4):2650-2660. PubMed ID: 34716781
[TBL] [Abstract][Full Text] [Related]
5. Change in forced vital capacity and associated subsequent outcomes in patients with newly diagnosed idiopathic pulmonary fibrosis.
Reichmann WM; Yu YF; Macaulay D; Wu EQ; Nathan SD
BMC Pulm Med; 2015 Dec; 15():167. PubMed ID: 26714746
[TBL] [Abstract][Full Text] [Related]
6. Acute Exacerbation and Decline in Forced Vital Capacity Are Associated with Increased Mortality in Idiopathic Pulmonary Fibrosis.
Paterniti MO; Bi Y; Rekić D; Wang Y; Karimi-Shah BA; Chowdhury BA
Ann Am Thorac Soc; 2017 Sep; 14(9):1395-1402. PubMed ID: 28388260
[TBL] [Abstract][Full Text] [Related]
7. The clinical relevance of lymphocyte to monocyte ratio in patients with Idiopathic Pulmonary Fibrosis (IPF).
Bernardinello N; Grisostomi G; Cocconcelli E; Castelli G; Petrarulo S; Biondini D; Saetta M; Spagnolo P; Balestro E
Respir Med; 2022 Jan; 191():106686. PubMed ID: 34847517
[TBL] [Abstract][Full Text] [Related]
8. Deterioration of high-resolution computed tomography findings predicts disease progression after initial decline in forced vital capacity in idiopathic pulmonary fibrosis patients treated with pirfenidone.
Higo H; Miyahara N; Taniguchi A; Senoo S; Itano J; Watanabe H; Oda N; Kayatani H; Ichikawa H; Shibayama T; Kajimoto K; Tanimoto Y; Kanehiro A; Maeda Y; Kiura K;
Respir Investig; 2020 May; 58(3):185-189. PubMed ID: 32102769
[TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of forced vital capacity decline prior to and following antifibrotic therapy in idiopathic pulmonary fibrosis.
Aono Y; Nakamura Y; Kono M; Nakamura H; Yokomura K; Imokawa S; Toyoshima M; Yasui H; Hozumi H; Karayama M; Suzuki Y; Furuhashi K; Enomoto N; Fujisawa T; Inui N; Suda T
Ther Adv Respir Dis; 2020; 14():1753466620953783. PubMed ID: 32928050
[TBL] [Abstract][Full Text] [Related]
10. EMPIRE Registry, Czech Part: Impact of demographics, pulmonary function and HRCT on survival and clinical course in idiopathic pulmonary fibrosis.
Doubková M; Švancara J; Svoboda M; Šterclová M; Bartoš V; Plačková M; Lacina L; Žurková M; Binková I; Bittenglová R; Lošťáková V; Merta Z; Šišková L; Tyl R; Lisá P; Šuldová H; Petřík F; Pšikalová J; Řihák V; Snížek T; Reiterer P; Homolka J; Musilová P; Lněnička J; Palúch P; Hrdina R; Králová R; Hortvíková H; Strenková J; Vašáková M
Clin Respir J; 2018 Apr; 12(4):1526-1535. PubMed ID: 28862397
[TBL] [Abstract][Full Text] [Related]
11. Real-life experiences in a single center: efficacy of pirfenidone in idiopathic pulmonary fibrosis and fibrotic idiopathic non-specific interstitial pneumonia patients.
Feng H; Zhao Y; Li Z; Kang J
Ther Adv Respir Dis; 2020; 14():1753466620963015. PubMed ID: 33070705
[TBL] [Abstract][Full Text] [Related]
12. Myositis-associated usual interstitial pneumonia has a better survival than idiopathic pulmonary fibrosis.
Aggarwal R; McBurney C; Schneider F; Yousem SA; Gibson KF; Lindell K; Fuhrman CR; Oddis CV
Rheumatology (Oxford); 2017 Mar; 56(3):384-389. PubMed ID: 28082622
[TBL] [Abstract][Full Text] [Related]
13. Variability of forced vital capacity in progressive interstitial lung disease: a prospective observational study.
Veit T; Barnikel M; Crispin A; Kneidinger N; Ceelen F; Arnold P; Munker D; Schmitzer M; Barton J; Schiopu S; Schiller HB; Frankenberger M; Milger K; Behr J; Neurohr C; Leuschner G
Respir Res; 2020 Oct; 21(1):270. PubMed ID: 33076914
[TBL] [Abstract][Full Text] [Related]
14. Prognosis of pulmonary fibrosis presenting with a usual interstitial pneumonia pattern on computed tomography in patients with myeloperoxidase anti-neutrophil cytoplasmic antibody-related nephritis: a retrospective single-center study.
Watanabe T; Minezawa T; Hasegawa M; Goto Y; Okamura T; Sakakibara Y; Niwa Y; Kato A; Hayashi M; Isogai S; Kondo M; Yamamoto N; Hashimoto N; Imaizumi K
BMC Pulm Med; 2019 Nov; 19(1):194. PubMed ID: 31675941
[TBL] [Abstract][Full Text] [Related]
15. Marginal decline in forced vital capacity is associated with a poor outcome in idiopathic pulmonary fibrosis.
Zappala CJ; Latsi PI; Nicholson AG; Colby TV; Cramer D; Renzoni EA; Hansell DM; du Bois RM; Wells AU
Eur Respir J; 2010 Apr; 35(4):830-6. PubMed ID: 19840957
[TBL] [Abstract][Full Text] [Related]
16. Using forced vital capacity (FVC) in the clinic to monitor patients with idiopathic pulmonary fibrosis (IPF): pros and cons.
Nathan SD; Wanger J; Zibrak JD; Wencel ML; Burg C; Stauffer JL
Expert Rev Respir Med; 2021 Feb; 15(2):175-181. PubMed ID: 32985286
[TBL] [Abstract][Full Text] [Related]
17. Effect of continued antifibrotic therapy after forced vital capacity decline in patients with idiopathic pulmonary fibrosis; a real world multicenter cohort study.
Adams CJ; Shapera S; Ryerson CJ; Assayag D; Johannson KA; Fell CD; Morisset J; Manganas H; Kolb M; Hambly N; Cox G; Khalil N; Marcoux V; Wilcox PG; To T; Sadatsafavi M; Halayko AJ; Gershon A; Garlick K; Fisher JH
Respir Med; 2022 Jan; 191():106722. PubMed ID: 34959146
[TBL] [Abstract][Full Text] [Related]
18. Impact of angiopoietin-1 and -2 on clinical course of idiopathic pulmonary fibrosis.
Uehara M; Enomoto N; Mikamo M; Oyama Y; Kono M; Fujisawa T; Inui N; Nakamura Y; Suda T
Respir Med; 2016 May; 114():18-26. PubMed ID: 27109807
[TBL] [Abstract][Full Text] [Related]
19. Disease progression in idiopathic pulmonary fibrosis without pulmonary function impairment.
Kondoh Y; Taniguchi H; Ogura T; Johkoh T; Fujimoto K; Sumikawa H; Kataoka K; Baba T; Colby TV; Kitaichi M
Respirology; 2013 Jul; 18(5):820-6. PubMed ID: 23489318
[TBL] [Abstract][Full Text] [Related]
20. Correlation of pulmonary function and usual interstitial pneumonia computed tomography patterns in idiopathic pulmonary fibrosis.
Arcadu A; Byrne SC; Pirina P; Hartman TE; Bartholmai BJ; Moua T
Respir Med; 2017 Aug; 129():152-157. PubMed ID: 28732823
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
